Immune checkpoint inhibitor-induced diarrhea and colitis: an overview

Keyphrases

• Colitis 100%
• Diarrhea 100%
• Immune Checkpoint Inhibitors 100%
• Immune-mediated Colitis 60%
• Risk Factors 40%
• Lymphocytes 20%
• Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 20%
• Treatment Efficacy 20%
• Neoplasms 20%
• Clinical Presentation 20%
• Overall Survival 20%
• Vomiting 20%
• Nausea 20%
• Clinical Management 20%
• Autoimmune Disease 20%
• Fever 20%
• Corticosteroids 20%
• Mucus 20%
• Integral Component 20%
• Treatment Toxicity 20%
• Abdominal Pain 20%
• Common Complications 20%
• Programmed Death-ligand 1 (PD-L1) 20%
• Current Management 20%
• Inflammatory Bowel Disease 20%
• Life-threatening Complications 20%
• Patient Care 20%
• Management Options 20%
• Infliximab 20%
• Replication Inhibitor 20%
• Refractory Cases 20%
• Gastrointestinal Side Effects 20%
• Bloody Stool 20%
• Clinical Workup 20%
• Gut Microbiota 20%
• Programmed Cell death-1/programmed Cell Death Ligand 1 20%
• Microbiota Transplantation 20%
• Vedolizumab 20%
• Checkpoint Inhibitor Colitis 20%
• Gastrointestinal Immune-related Adverse Events 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Colitis 100%
• Diarrhea 100%
• Immune Checkpoint Inhibitor 100%
• Adverse Event 28%
• Neoplasm 14%
• Side Effect 14%
• Overall Survival 14%
• Cytokine 14%
• Programmed Cell Death 14%
• Autoimmune Disease 14%
• Nausea and Vomiting 14%
• Abdominal Pain 14%
• Immunosuppressive Agent 14%
• Inflammatory Bowel Disease 14%
• Programmed Death 1 Ligand 1 14%
• Infliximab 14%
• Intestine Flora 14%
• Microflora 14%
• Vedolizumab 14%

Medicine and Dentistry

• Blood in Stool 14%